ArticleBMC medicine2026
Association between preoperative interruption of antiplatelet therapy and postoperative thrombotic risk after minimally invasive surgery for abdominopelvic cancer in patients treated with P2Y12 inhibitors.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety of preoperative discontinuation of antiplatelet therapy for arterial thrombotic complications in non-cardiac, high-bleeding-risk surgery among patients receiving P2Y12 inhibitors remains poorly understood. This study compares the effect of preoperative discontinuation of antiplatelet therapy versus maintenance on thrombotic complications in patients receiving P2Y12 inhibitors who undergo minimally invasive surgery (MIS) for abdominal or pelvic cancer.
methodsIn this cohort study, we identified patients receiving P2Y12 inhibitors who underwent planned MIS for abdominopelvic cancer from two hospital-based databases. They were divided into an interruption (exposure) group that discontinued antiplatelet therapy 5 days before surgery and a maintenance (control) group that continued therapy based on confirmed prescriptions less than 5 days before surgery. After adjusting for confounders, we evaluated the weighted risk ratios (RRs) for postoperative interventions over 90 days.
resultsA total of 1365 eligible patients were divided into an interruption group (n = 1157) and a maintenance group (n = 208). The interruption group had increased risk of thrombotic complications (RR, 3.29; 95% confidence interval (CI), 1.15 to 9.41), particularly in postoperative coronary artery disease (RR, 5.30; 95% CI, 1.27 to 22.12). This elevated risk was notable among patients receiving dual antiplatelet therapy preoperatively. The interruption group did not show increased risk of postoperative ischemic stroke or peripheral arterial disease, nor did it substantially differ in hemostasis procedures, blood transfusions, or mortality. Notably, patients who discontinued antiplatelet therapy exhibited a higher overall risk of vascular events (RR, 2.54; 95% CI, 1.16 to 5.56).
conclusionsDiscontinuing antiplatelet therapy in patients receiving P2Y12 inhibitors more than 5 days before MIS was associated with an increased risk of postoperative coronary artery disease, without providing any benefit in terms of bleeding control or mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.